Meeting
2020 ASCO Virtual Scientific Program
Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.
Authors
Ugo De Giorgi
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
Ugo De Giorgi , Giuseppe Schepisi , Giorgia Gurioli , Carmela Pisano , Umberto Basso , Cristian Lolli , Elisabetta Petracci , Chiara Casadei , Sabrina Chiara Cecere , Laura Attademo , Alberto Clemente , Valentina Zampiga , Valentina Galla , Ilaria Cangini , Marilena Di Napoli , Linda Valmorri , Sandro Pignata
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Germ Cell/Testicular
Clinical Trial Registration Number
NCT02533765
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5058)
DOI
10.1200/JCO.2020.38.15_suppl.5058
Abstract #
5058
Poster Bd #
127
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumors (GCT).
First Author: Jennifer King
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2012 ASCO Annual Meeting
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2024 ASCO Genitourinary Cancers Symposium
Novel molecular aberrations involved in testicular germ cell tumor (TGCT) development and cisplatin resistance.
First Author: Ludmila Boublikova